Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia
Sponsor
Novartis Pharmaceuticals (Industry)
Overall Status
Completed
CT.gov ID
NCT00099216
Collaborator
(none)
708
63
51
11.2
0.2
Study Details
Study Description
Brief Summary
The goal of this research study is to evaluate the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 3 |
Study Design
Study Type:
Interventional
Actual Enrollment
:
708 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia
Study Start Date
:
Aug 1, 2001
Actual Primary Completion Date
:
Nov 1, 2005
Actual Study Completion Date
:
Nov 1, 2005
Outcome Measures
Primary Outcome Measures
- Change in cognition from baseline at week 24 []
- Global clinical impression of change from baseline at week 24 []
Secondary Outcome Measures
- Change in activities of daily living from baseline at week 24 []
- Change in behavioral symptoms from baseline at week 24 []
- Change in clinical staging from baseline at week 24 []
Eligibility Criteria
Criteria
Ages Eligible for Study:
50 Years
to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Between the ages of 50 and 85 years old
-
Have contact with a responsible caregiver 3 or more days per week
-
Be male or a female who is surgically sterilized or one year post menopausal
Exclusion Criteria:
-
Current diagnosis of severe or unstable cardiovascular or other diseases
-
Current diagnosis of active, uncontrolled seizure disorder, Parkinson's disease or Alzheimer's disease
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Irvine | California | United States | 92618 | |
2 | San Francisco | California | United States | 94109 | |
3 | Boynton Beach | Florida | United States | 33426 | |
4 | Miami Beach | Florida | United States | 33140 | |
5 | Port Charlotte | Florida | United States | ||
6 | Indianapolis | Indiana | United States | 46202 | |
7 | Des Moines | Iowa | United States | 50314 | |
8 | St. Louis | Missouri | United States | ||
9 | Albuquerque | New Mexico | United States | ||
10 | New York | New York | United States | 10003 | |
11 | Portland | Oregon | United States | 97223 | |
12 | Allentown | Pennsylvania | United States | 18103 | |
13 | Greensburg | Pennsylvania | United States | 15601 | |
14 | Charleston | South Carolina | United States | 29406 | |
15 | Austin | Texas | United States | 78756 | |
16 | Houston | Texas | United States | 77030 | |
17 | Bennington | Vermont | United States | 05201 | |
18 | Graz | Austria | |||
19 | Linz | Austria | |||
20 | Wien | Austria | |||
21 | Edmonton | Alberta | Canada | ||
22 | Ottawa | Ontario | Canada | ||
23 | Toronto | Ontario | Canada | ||
24 | Montreal | Quebec | Canada | ||
25 | Amiens | France | |||
26 | Bordeaux | France | |||
27 | Lille Cedex | France | |||
28 | Marseille | France | |||
29 | Montpellier Cedex | France | |||
30 | Toulouse | France | |||
31 | Tours Cedex | France | |||
32 | Bautzen | Germany | |||
33 | Berlin | Germany | |||
34 | Bochum | Germany | |||
35 | Chemnitz | Germany | |||
36 | Eisenhuttenstadt | Germany | |||
37 | Erlangen | Germany | |||
38 | Freiburg | Germany | |||
39 | Luedenscheid | Germany | |||
40 | Osnabrueck | Germany | |||
41 | Ancona | Italy | |||
42 | Brescia | Italy | |||
43 | Firenze | Italy | |||
44 | Perugia | Italy | |||
45 | Reggio Emilia | Italy | |||
46 | Roma | Italy | |||
47 | Vicenza | Italy | |||
48 | Moscow | Russian Federation | |||
49 | Saint-Petersburg | Russian Federation | |||
50 | Barakaldo | Spain | |||
51 | Barcelona | Spain | |||
52 | Madrid | Spain | |||
53 | Pamplona | Spain | |||
54 | Saint Cugat del Valles | Spain | |||
55 | Basel | Switzerland | |||
56 | Lausanne | Switzerland | |||
57 | Newcastle Upon Tyne | Newcastle | United Kingdom | ||
58 | Swindon | Wiltshire | United Kingdom | ||
59 | Bristol | United Kingdom | |||
60 | Clydebank | United Kingdom | |||
61 | East Sussex | United Kingdom | |||
62 | Southampton | United Kingdom | |||
63 | St Annes | United Kingdom |
Sponsors and Collaborators
- Novartis Pharmaceuticals
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.Responsible Party:
Novartis Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00099216
Other Study ID Numbers:
- CENA713BIA05
First Posted:
Dec 10, 2004
Last Update Posted:
Nov 17, 2011
Last Verified:
Nov 1, 2011
Keywords provided by Novartis Pharmaceuticals
Additional relevant MeSH terms: